Biocryst Pharmaceuticals (BCRX) Revenue (2010 - 2026)
Biocryst Pharmaceuticals' (BCRX) quarterly Revenue came in at $156.4 million in Q1 2026, up 7.48% YoY from $145.5 million in Q1 2025, and up 21992.23% on a QoQ basis from $708000.0 in Q4 2025.
Biocryst Pharmaceuticals (BCRX) Revenue (2010 - 2026) Analysis & Trends
Biocryst Pharmaceuticals (BCRX) has 17 years of Revenue data on file, last reported at $156.4 million in Q1 2026.
- Quarterly Revenue rose 7.48% year-over-year to $156.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $479.9 million (down 4.69% YoY) and the FY2025 annual result came in at $874.8 million, up 94.1% from the prior year.
- Revenue advanced to $156.4 million in Q1 2026, from $708000.0 in the prior quarter.
- In the past five years, Revenue ranged from a high of $163.4 million in Q2 2025 to a low of $708000.0 in Q4 2025.
- A 5-year average of $98.7 million and a median of $92.8 million in 2024 frame the typical range for Revenue.
- Annual changes were most pronounced in 2022 — Revenue surged 161.94% — and 2025, when it sank 99.46%.
- Tracing BCRX's Revenue over 5 years: stood at $79.5 million in 2022, then grew by 17.42% to $93.4 million in 2023, then jumped by 40.83% to $131.5 million in 2024, then slumped by 99.46% to $708000.0 in 2025, then surged by 21992.23% to $156.4 million in 2026.
- The last three Revenue figures came in at $156.4 million (Q1 2026), $708000.0 (Q4 2025), and $159.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 4.14 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 2.47 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 7.65 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 783.30 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 3.76 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 959.00 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 1.37 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Biocryst Pharmaceuticals | 2.46 Bn | 2.10 Bn | 214.41 Mn | 218.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 218.25 Mn |
| Mar 31, 2026 | 156.41 Mn |
| Dec 31, 2025 | 708,000.00 |
| Sep 30, 2025 | 159.40 Mn |
| Jun 30, 2025 | 163.35 Mn |
| Mar 31, 2025 | 145.53 Mn |
| Dec 31, 2024 | 131.53 Mn |
| Sep 30, 2024 | 117.09 Mn |
| Jun 30, 2024 | 109.33 Mn |
| Mar 31, 2024 | 92.76 Mn |
| Dec 31, 2023 | 93.40 Mn |
| Sep 30, 2023 | 86.74 Mn |
| Jun 30, 2023 | 82.49 Mn |
| Mar 31, 2023 | 68.78 Mn |
| Dec 31, 2022 | 79.55 Mn |
| Sep 30, 2022 | 75.83 Mn |
| Jun 30, 2022 | 65.53 Mn |
| Mar 31, 2022 | 49.92 Mn |
| Dec 31, 2021 | 47.16 Mn |
| Sep 30, 2021 | 40.99 Mn |